HuGE Literature Finder
Records 1-30
|
Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
Cancer biomarkers : section A of Disease markers 2021 May . Arrieta Oscar, Hernández-Martínez Juan-Manuel, Montes-Servín Edgar, Heredia David, Cardona Andrés F, Molina-Romero Camilo, Lara-Mejía Luis, Diaz-Garcia Diego, Bahena-Gonzalez Antonio, Mendoza-Oliva Dolores |
|
NGS-based liquid-biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step towards personalized NSCLC treatment.
Molecular oncology 2021 May . Sánchez-Herrero Estela, Serna-Blasco Roberto, Ivanchuk Vadym, García-Campelo Rosario, Dómine Gómez Manuel, Miguel Sánchez José, Massutí Bartomeu, Reguart Noemi, Camps Carlos, Sanz-Moreno Sandra, Calabuig-Fariñas Silvia, Jantus-Lewintre Eloísa, Arnal Magdalena, Fernández-Orth Dietmar, Calvo Virginia, González-Rumayor Víctor, Provencio Mariano, Romero Atoc |
|
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Targeted oncology 2021 Feb . Cheng Ying, He Yong, Li Wei, Zhang He-Long, Zhou Qing, Wang Buhai, Liu Chunling, Walding Andrew, Saggese Matilde, Huang Xiangning, Fan Minhao, Wang Jia, Ramalingam Suresh |
|
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Clinical lung cancer 2021 Feb . Ferrara Miriam Grazia, Martini Maurizio, D'Argento Ettore, Forcella Chiara, Vita Emanuele, Di Noia Vincenzo, Sperduti Isabella, Bilotta Mirna, Ribelli Marta, Damiano Paola, Cannella Antonella, Stefani Alessio, Pilotto Sara, Carbone Carmine, Piro Geny, Milella Michele, Tortora Giampaolo, Bria Emil |
|
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
Cancer chemotherapy and pharmacology 2021 Jan . Verheijen R B, van Duijl T T, van den Heuvel M M, Vessies D, Muller M, Beijnen J H, Janssen J M, Schellens J H M, Steeghs N, van den Broek D, Huitema A D |
|
Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
Cancer management and research 2021 13 2033-2039. Peng Da, Shan Dongfeng, Dai Chengcheng, Li Jie, Wang Zifan, Huang Ziyi, Peng Rui, Zhao Peng, Ma Xuezh |
|
First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Thoracic cancer 2020 Dec . Su Po-Lan, Chen Chian-Wei, Wu Yi-Lin, Lin Chien-Chung, Su Wu-Ch |
|
MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Clinical colorectal cancer 2020 Dec . Chuang Jeremy, Wang Chongkai, Guo Yuming, Valenzuela Valerie, Wu Jun, Fakih Marw |
|
Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Cureus 2020 Dec 12 (12): e12128. Pereira Isabel, Gaspar Cátia, Pina Marta, Azevedo Isabel, Rodrigues A |
|
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Lung cancer (Amsterdam, Netherlands) 2020 Nov 151 20-24. Yamamoto N, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Yamanaka T, Tanaka M, Takahashi K, Fukuoka |
|
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
EBioMedicine 2020 Nov 62 103103. Dietz Steffen, Christopoulos Petros, Yuan Zhao, Angeles Arlou Kristina, Gu Lisa, Volckmar Anna-Lena, Ogrodnik Simon J, Janke Florian, Fratte Chiara Dalle, Zemojtel Tomasz, Schneider Marc A, Kazdal Daniel, Endris Volker, Meister Michael, Muley Thomas, Cecchin Erika, Reck Martin, Schlesner Matthias, Thomas Michael, Stenzinger Albrecht, Sültmann Holg |
|
EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients.
Thoracic cancer 2020 Sep . Leal Leticia F, Laus Ana C, Cavagna Rodrigo, de Paula Flavia E, de Oliveira Marco A, Ribeiro Dayana M, Hassan Fernanda M, Miziara José E, da Silva Eduardo C Albino, da Silva Vinicius D, De Marchi Pedro, Reis Rui |
|
Erlotinib and bevacizumab in elderly patients =75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Investigational new drugs 2020 Aug . Aoshima Yoichiro, Karayama Masato, Inui Naoki, Yasui Hideki, Hozumi Hironao, Suzuki Yuzo, Furuhashi Kazuki, Fujisawa Tomoyuki, Enomoto Noriyuki, Nakamura Yutaro, Mikamo Masashi, Matsuura Shun, Kusagaya Hideki, Kaida Yusuke, Uto Tomohiro, Hashimoto Dai, Matsui Takashi, Asada Kazuhiro, Suda Takafu |
|
Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
Carcinogenesis 2020 Aug . Li Yankang, Zhang Nasha, Zhang Li, Song Yemei, Liu Jie, Yu Jinming, Yang Mi |
|
Detection of Low-level EGFR c.2369 C?>?T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes.
Pathology oncology research : POR 2020 Jun . Ye Linda, Mesbah Ardakani Nima, Thomas Carla, Spilsbury Katrina, Leslie Connull, Amanuel Benhur, Millward Micha |
|
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Cancer 2020 Feb . Takahama Takayuki, Azuma Koichi, Shimokawa Mototsugu, Takeda Masayuki, Ishii Hidenobu, Kato Terufumi, Saito Haruhiro, Daga Haruko, Tsuboguchi Yuko, Okamoto Isamu, Otsubo Kohei, Akamatsu Hiroaki, Teraoka Shunsuke, Takahashi Toshiaki, Ono Akira, Ohira Tatsuo, Yokoyama Toshihide, Sakai Kazuko, Yamamoto Nobuyuki, Nishio Kazuto, Nakagawa Kazuhi |
|
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
BMC cancer 2020 Jan 20 (1): 76. Liu Kejun, Jiang Guanming, Zhang Ailing, Li Zhuanghua, Jia J |
|
IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER.
Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery 2020 33 (3): e1524. Zanatto Renato Morato, Santos Gianni, Oliveira Júnea Caris, Pracucho Eduardo Marcucci, Nunes Adauto José Ferreira, Lopes-Filho Gaspar Jesus, Saad Sarhan Sydn |
|
Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
PloS one 2020 15 (12): e0244502. Chen Yu-Hung, Wang Tso-Fu, Chu Sung-Chao, Lin Chih-Bin, Wang Ling-Yi, Lue Kun-Han, Liu Shu-Hsin, Chan Sheng-Chi |
|
Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis.
Cancer medicine 2019 Dec . Bylsma Lauren C, Gillezeau Christina, Garawin Tamer A, Kelsh Michael A, Fryzek Jon P, Sangaré Laura, Lowe Kimberly |
|
When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival.
Asia-Pacific journal of clinical oncology 2019 Dec . Kwok Wang Chun, Ho James Chung Man, Lam David Chi Leung, Lui Macy Mei Sze, Ip Mary Sau Man, Tam Terence Chi Ch |
|
Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study.
Targeted oncology 2019 Nov . Yang Zhengquan, Li Jialu, Hu Yujie, Chen Meihua, Peng Danli, Zong Dan, Shang Qingjuan, Tao Lianqin, Zhao Yanling, Ni Yiyun, Ye Jinyan, Xie Yupeng, Yang Li, Lin Quan, Cai Chang, Xu Ning, Huang Xiaoping, Dong Xiaoting, Zhou Zhonghui, Yu Yali, Shangguan Zongxiao, Xu Yangyang, Ying Weiping, Weng Meiling, Yuan Zuguo, Dong Zhijun, Li Jifa, Zheng Zhe, Pan Jiongwei, Liu Lu, Ye Junhui, Zhang Zhan, Li Wenfeng, Zhu Junfei, Jin Shengnan, Li Yuping, Ding Chunmi |
|
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Cancer medicine 2019 Nov . Lei Lei, Wang Wen-Xian, Zhu You-Cai, Li Jin-Luan, Fang Yong, Wang Hong, Zhuang Wu, Zhang Yin-Bin, Wang Li-Ping, Fang Mei-Yu, Xu Chun-Wei, Wang Xiao-Jia, Lv Tang-Feng, Song Yo |
|
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
Clinical genitourinary cancer 2019 Nov . Chapman Lynne, Ledet Elisa M, Barata Pedro C, Cotogno Patrick, Manogue Charlotte, Moses Marcus, Christensen Bryce R, Steinwald Peter, Ranasinghe Lahiru, Layton Jodi L, Lewis Brian E, Sartor Oliv |
|
Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases.
Oncology research 2019 Oct . Xu Jianping, Liu Xiaoyan, Yang Sheng, Shi Yuank |
|
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
BMC cancer 2019 Oct 19 (1): 1006. Chen Yung-Hsuan, Chen Yen-Fu, Chen Chung-Yu, Shih Jin-Yuan, Yu Chong-J |
|
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Clinical lung cancer 2019 Aug . Dal Maso Alessandro, Lorenzi Martina, Roca Elisa, Pilotto Sara, Macerelli Marianna, Polo Valentina, Cecere Fabiana Letizia, Del Conte Alessandro, Nardo Giorgia, Buoro Vanessa, Scattolin Daniela, Monteverdi Sara, Urso Loredana, Zulato Elisabetta, Frega Stefano, Bonanno Laura, Indraccolo Stefano, Calabrese Fiorella, Conte PierFranco, Pasello Giul |
|
Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
Journal of thoracic disease 2019 Jul 11 (7): 3004-3014. Li Yue, Xu Yuxia, Wu Xiaoyan, He Caiyun, Liu Qing, Wang Fa |
|
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Annals of oncology : official journal of the European Society for Medical Oncology 2019 May 30 (5): 796-803. Santos C, Azuara D, Viéitez J M, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Aranda E, Salazar |
|
Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer.
In vivo (Athens, Greece) 0 34 (4): 2179-2185. Lim Jeong Uk, Yeo Chang Dong, Kim Hyung Woo, Kang Hye Seon, Park Chan Kwon, Kim Ju Sang, Kim Jin Woo, Kim Seung Joon, Lee Sang Ha |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jun 16, 2021
- Content source: